Karyopharm Therapeutics faces liquidity crunch as myelofibrosis drug nears FDA review
The US biotech firm’s cash reserves are set to run out by September, creating a critical financing deadline just as it prepares to submit its combination therapy for accelerated approval.
Karyopharm Therapeutics has revealed a critical liquidity challenge as it prepares to submit its myelofibrosis combination therapy for review by the US Food and Drug Administration. The company, which reported its second-quarter results on 13 August, holds $65.4 million in cash, a sum management states is sufficient to fund operations only until September 2026. This financial position creates a tight timeline for the firm, which is currently evaluating financing and strategic alternatives to bridge the gap.
The immediate pressure stems from a $15.8 million term loan payment due on 10 September. Management has warned that if this payment is made without securing new financing or obtaining a lender waiver, the company’s cash balance would fall below the $10 million minimum liquidity covenant. Such a breach would trigger an event of default, adding a layer of financial risk to the company’s ongoing clinical developments.
Despite the balance sheet concerns, the clinical data supporting the company’s lead candidate remains robust. The Phase III SENTRY study demonstrated that the combination of selinexor and ruxolitinib nearly doubled the spleen response rate compared with ruxolitinib alone. Responses were observed as early as week 12 and sustained through week 36, with an overall survival hazard ratio of 0.43 at the time of topline analysis. If approved, this would represent the first combination therapy for frontline myelofibrosis, a condition affecting approximately 20,000 people in the US.
The company plans to submit the therapy for FDA review this month under the Accelerated Approval Pathway. Karyopharm estimates the peak US revenue opportunity for the drug at up to $1 billion, intending to leverage its existing commercial infrastructure for XPOVIO to drive rapid adoption. XPOVIO itself generated $30.8 million in US net product revenue in the quarter, with demand remaining roughly flat year-on-year.
However, the broader financial picture has deteriorated. Total revenue fell to $33.4 million from $37.9 million in the same period last year, largely due to the end of Menarini’s reimbursement of development costs in late 2025. Consequently, the net loss widened to $67 million from $37.3 million, partly reflecting non-cash mark-to-market adjustments. Additionally, a Phase III trial for endometrial cancer missed its primary endpoint, prompting the company to scale back that programme and refocus its strategy on myelofibrosis and multiple myeloma.
Market sentiment remains divided as investors weigh the clinical potential against the financial risks. Hedge fund ownership increased to 24 funds from 21 in the prior quarter, indicating some institutional interest. However, short interest stands at 33.51% of the float, signalling significant skepticism. With the sNDA submission and the September loan payment looming, the coming weeks will be decisive for Karyopharm’s future.
